Resting energy expenditure of patients with gynecologic malignancies.
OBJECTIVE
To evaluate resting energy expenditure compared to predicted energy expenditure in patients with cervical or ovarian carcinoma who require specialized nutritional support.


METHODS
Women with biopsy-proven cervical or ovarian carcinoma referred to the Nutrition Support Service were studied. Resting energy expenditure was measured by indirect calorimetry and compared to predicted energy expenditure (PEE) as determined by the Harris-Benedict equation for females.


RESULTS
Sixty one patients were studied. Patients with ovarian cancer (n = 31) had a significantly higher measured resting energy expenditure (% PEE) than patients with cervical cancer (109 +/- 18% vs. 98 +/- 16%, p < 0.02, respectively). This difference in measured resting energy expenditure between groups could not be explained by differences in the extent of disease, nutritional status, body temperature, or nutrient intake between groups. A greater proportion of patients with ovarian cancer were hypermetabolic (> 110% of predicted) in comparison to patients with cervical cancer (55% vs. 13%, p < 0.01, respectively). Measured resting energy expenditure varied between 53% and 157% of predicted for the entire population.


CONCLUSIONS
Ovarian cancer patients are more hypermetabolic than cervical cancer patients. The Harris-Benedict equation for females is a unreliable estimate of caloric expenditure in patients with cervical or ovarian cancer receiving specialized nutritional support.
Department of Clinical Pharmacy, University of Tennessee, Memphis 38163, USA.
R N
RN
Dickerson
K G
KG
White
P G
PG
Curcillo
S A
SA
King
J L
JL
Mullen
D000328:Adult; D000368:Aged; D001481:Basal Metabolism; D002153:Calorimetry, Indirect; D005260:Female; D006801:Humans; D008875:Middle Aged; D015596:Nutrition Assessment; D018529:Nutritional Support; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000628:therapy; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012146:Rest; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000628:therapy